stockrowCharles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. (CRL) Return on equity
Charles River Laboratories International, Inc.'s return on equity over the twelve months to 30 September 2026 was 1.21%, up 5.6 percentage points from fiscal 2025 (−4.35%). Over the past ten years it has ranged from −4.35% (fiscal 2025) to 21.1% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −4.35% | (4.64) |
| FY2024 | 0.29% | (14.13) |
| FY2023 | 14.4% | (3.20) |
| FY2022 | 17.6% | 0.83 |
| FY2021 | 16.8% | (2.61) |
| FY2020 | 19.4% | 2.36 |
| FY2019 | 17.0% | (2.09) |
| FY2018 | 19.1% | 6.05 |
| FY2017 | 13.1% | (6.55) |
| FY2016 | 19.6% | (1.50) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 153.9% |
| MEDP Medpace Holdings, Inc. compare | 117.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| QGEN QIAGEN N.V. compare | 11.9% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| ICLR ICON PLC compare | 4.86% |
| CRL Charles River Laboratories International, Inc. | 1.21% |
| RVTY Revvity Inc. compare | 0.00% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement